PRECIGEN pipeline

Discovery
by Design

Our growing pipeline of multifunctional gene and cell therapy candidates gives us distinct advantages for combination strategies. Our preclinical and clinical pipeline includes several programs leveraging our technologies in core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases.

Clinical Pipeline

As of July 5, 2022

Preclinical Pipeline

As of July 5, 2022
Therapeutic AreaProductPlatformIndicationDiscoveryPreclinicalPhase 1Phase 2Phase 3
Immuno-OncologyPRGN-3008UltraCAR-TUndisclosed
Immuno-OncologyPRGN-5001Multifunctional TherapeuticSolid Tumors
Immuno-OncologyPRGN-2010OTS AdenoVerse ImmunotherapySolid Tumors
Immuno-OncologyPRGN-2011AdenoVerse Cytokine TherapySolid Tumors
Immuno-OncologyPRGN-5002Multifunctional TherapeuticSolid Tumors
Infectious DiseasePRGN-2013OTS AdenoVerse ImmunotherapyChronic Hepatitis B
Autoimmune DisordersAG017ActoBioticsCeliac Disease
Autoimmune DisordersPRGN-3009UndisclosedUndisclosed
Autoimmune DisordersPRGN-3010UndisclosedUndisclosed

Expanded Access Policy

Download Policy

For physicians seeking pre-approval access to one of our investigational therapies, please review our expanded access policy. For expanded access inquiries, please contact us at expandedaccess@precigen.com.

Download Policy